aspsirna0918 details

''''
ASPsiRNA information siRNA Id:aspsirna0918
siRNA Name: Sibeta2m03
Mismatch information Wild siRNA (As strand 3'->5'):AGGUAGGCUGUAACUUCAA
ASP-siRNA (As strand 3'->5'):AGGUAGGCUGUAACUUGAA
Mismatch position in siRNA: G3C
Gene Information Gene Name Beta 2-microglobulin (B2M)
Target Sequence (5'->3'):ATTGAAAAAGTGGAGCATTCAGACT
Wild allele (5'->3'):UCCAUCCGACAUUGAAGUU
Mutant allele (5'->3'):UCCAUCCGACAUUGAACUU
Position of siRNA on target gene: 213-231
Respective Gene/Protein Resources GenBank Accession:NM_004048.2
Cytogenic location:15q21.1
Chromosomal coordinates:15:45,003,684-45,010,356
UniProt ID:P61769
HUGO ID:914
Reference SNp(RefSNP): rs10489448
Disease/Mutation information Target Mutation: c.31G>C,p.Ala11Pro
Matation type/variant: Single nucleotide variant/Missense variant
Mutation at gene level: NG_012920.1:g.5091G>C
Pathogenic status of mutation: Pathogenic
Disease:HLA incompatibility
Clinical Resources ClinVar ID:17740
KEGG disease ID:NA
OMIM ID: NA
COSMIC: B2M
DECIPHER: B2M
GeneTests: B2M
ASP siRNA details Mutant allele (5'->3'): UCCAUCCGACAUUGAACUU
ASP-siRNA (As strand 3'->5'):AGGUAGGCUGUAACUUGAA
Percentage efficacy of ASP-siRNA for mutant allele:75
Wild allele (5'->3'): UCCAUCCGACAUUGAAGUU
ASP-siRNA (As strand 3'->5'):AGGUAGGCUGUAACUUGAA
Percentage efficacy of ASP-siRNA for wild allele:NA
Relative difference:NA
Wild siRNA details Wild allele (5'->3'): UCCAUCCGACAUUGAAGUU
Wild siRNA (As strand 3'->5'):AGGUAGGCUGUAACUUCAA
Percentage efficacy of wild siRNA for wild allele:50
Wild allele (5'->3'): UCCAUCCGACAUUGAAGUU
ASP-siRNA (As strand 3'->5'):AGGUAGGCUGUAACUUGAA
Percentage efficacy of Wild sirna for mutant allele:90
Relative difference :-40
General information Mismatch incorporated in siRNA/Target:siRNA
Cell-line used: HeLa
Experimental technique used: Western blot
Transfection method: RNAiFect
siRNA expression method: Ambion
Post-transfection duration: 48 hours
Concentration used:1.2mIcrog
Reference:16520945
Delivery method:Lentiviral vector delivery
Article title:Class-, gene-, and group-specific HLA silencing by lentiviral shRNA delivery.
Authors:Figueiredo C, Seltsam A, Blasczyk R.
Journal Reference:J Mol Med (Berl). 2006 May;84(5):425-37. Epub 2006 Mar 7.